CalciMedica Q3 Loss Narrows to $1.7M on $13.8M Cash

CalciMedica (Nasdaq: CALC) reported a third-quarter 2026 net loss of $1.7 million, or $0.24 per basic and diluted share, on November 10, 2026, a sharp reduction from the $7.8 million loss, or $2.59 per share, recorded in the same quarter a year earlier. The clinical-stage biopharmaceutical company ended the period with $13.8 million in cash, cash equivalents and short-term investments, which it expects to fund operations into the second half of 2027.

The company said data from an Auxora Phase 1b proof-of-concept trial in pulmonary hypertension and an investigational new drug submission for CM5480 are both anticipated in mid-2027.

Context — why the cash runway and loss reduction matter now

The headline numbers alone do not explain why this quarter matters. The $6.1 million year-over-year narrowing in quarterly net loss is not primarily an operating improvement. It is driven by a $3.1 million noncash gain in other income, tied to changes in the fair value of the company's financial instruments, according to the report. That distinction is central for anyone reading the results as evidence of a turnaround.

The operating picture is more mixed. Research and development expenses fell to $2.3 million for the quarter from $3.9 million a year earlier, and to $7.9 million for the nine-month period from $12.1 million. The company attributed the $4.2 million nine-month decline to reduced nonclinical and clinical trial activity, lower consultant spend, and decreased chemistry, manufacturing and controls work, partly offset by higher personnel costs.

General and administrative expenses moved the other way on a quarterly basis, rising to $2.4 million from $1.8 million, though the nine-month figure was roughly flat at $6.5 million versus $6.6 million.

A one-for-five reverse stock split took effect August 31, 2026, reducing issued and outstanding shares from approximately 34.5 million to approximately 6.9 million. The company said the move brought it into compliance with Nasdaq's minimum bid price requirement for continued listing. That compliance is a live issue for a clinical-stage issuer whose equity value depends heavily on trial outcomes.

The balance sheet also shifted materially. Total liabilities fell to $10.1 million from $20.2 million at December 31, 2025, and stockholders' equity moved to positive $4.2 million from a deficit of $6.6 million. The warrant liability declined to $300,000 from $8.0 million over the same period.

Data — what the numbers show

The quarter's reported figures, set against the prior-year period, show the magnitude of the change:

Metric	Q3 2026	Q3 2025
Net loss	$1.7M	$7.8M
Net loss per share	$0.24	$2.59
R&D expenses	$2.3M	$3.9M
G&A expenses	$2.4M	$1.8M
Other income/(expense)	$3.1M income	$2.2M expense

For the nine months ended September 30, 2026, net loss was $4.4 million, or $0.96 per share, compared with $18.8 million, or $6.61 per share, a year earlier. Total other income for the nine-month period was $10.0 million versus a $0.1 million expense in the prior-year period, a $10.1 million swing the company again tied to fair value changes on its financial instruments.

Cash and cash equivalents stood at $4.6 million, with a further $9.2 million in short-term investments. Total current assets were $14.2 million against total current liabilities of $2.9 million.

No revenue line appears in the reported operating results. The company also did not disclose the terms of the additional financing it says the planned Phase 2b acute pancreatitis trial depends on.

Analysis — what it means for CALC and the sector

The read-through for CALC holders is a company that has bought time but not yet bought proof. A runway into the second half of 2027 covers the mid-2027 Auxora Phase 1b data readout and the CM5480 IND submission, but it leaves little margin for delay. The acute pancreatitis Phase 2b trial is explicitly subject to additional financing, meaning the registration path the company describes is not yet fully funded.

The company's differentiation argument rests on mechanism rather than existing clinical data in pulmonary hypertension. CalciMedica said preclinical models suggest CRAC channel inhibition may target multiple disease drivers, including right ventricular dysfunction, which it describes as the principal cause of mortality and not directly targeted by existing therapies. That claim is preclinical, and the Phase 1b trial is designed to generate the first clinical evidence for it.

The counter-argument is the KOURAGE experience. In that Phase 2 trial in acute kidney injury with respiratory failure, enrollment was paused in January 2026 following a mortality imbalance. The company said no drug-related toxicity was identified and that FDA reviewed a protocol amendment and interim safety data without comments or questions, allowing development of Auxora to proceed. CalciMedica does not plan to restart KOURAGE at this time.

Positioning is likely to stay event-driven. With no revenue and a binary clinical calendar, flow tends to concentrate around disclosure dates rather than fundamentals, and the mid-2027 window is the next scheduled inflection for both lead programs.

Outlook — what to watch next

Three scheduled items define the near-term calendar. First, the company expects to disclose details on the Phase 1b pulmonary hypertension trial and its target patient population by year-end 2026. Second, Auxora Phase 1b proof-of-concept data are anticipated in mid-2027. Third, the CM5480 IND submission is also anticipated in mid-2027.

The acute pancreatitis Phase 2b trial remains the open variable, because initiation is subject to additional financing the company has not yet secured or priced. Any announcement on that financing is the clearest near-term signal on how much of the pipeline can advance on schedule.

On the listing side, the reverse split delivered compliance with Nasdaq's minimum bid price requirement. Sustaining that compliance is the mechanical threshold to watch, since a return below the minimum would put continued listing back in question.

Frequently Asked Questions

What does CalciMedica's Q3 2026 loss mean for retail investors?

The $1.7 million net loss is smaller than the prior-year quarter, but $3.1 million of it came from a noncash fair value gain rather than operations. Investors should separate that accounting item from the underlying cash burn. The company held $13.8 million in cash, cash equivalents and short-term investments and guided to a runway into the second half of 2027.

What happens next for CalciMedica's pipeline?

The company expects to disclose Phase 1b pulmonary hypertension trial details and its target patient population by year-end 2026. Auxora Phase 1b proof-of-concept data and the CM5480 IND submission are both anticipated in mid-2027. The acute pancreatitis Phase 2b trial is planned but subject to additional financing, and CalciMedica does not intend to restart the KOURAGE trial.

Why did CalciMedica's research and development costs fall?

Nine-month R&D expenses dropped to $7.9 million from $12.1 million, a $4.2 million decline. CalciMedica attributed the decrease mainly to lower nonclinical and clinical trial activity, reduced consultant spend, and fewer chemistry, manufacturing and controls activities, partly offset by higher personnel costs. Quarterly R&D fell to $2.3 million from $3.9 million.

Bottom Line

CalciMedica has funded itself into the second half of 2027, but both lead clinical catalysts and the financing for its pancreatitis trial remain unresolved.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.